Computational Biology Approach to Predict Hypomethylating Agent (HMA) Response Using Genomic and Clinical Characteristics in Myelodsyplastic Syndromes (MDS)

Background: HMAs (e.g., azacitidine (AZA), decitabine (DAC)) are approved agents for the treatment of patients with MDS. Despite their widespread use, only 50% of patients respond to HMA without reliable biomarkers of response despite knowing the patient’s genomic and clinical (non-genomic) characteristics prior to treatment.